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Abstract
Background: The hypogonadal (hpg) mouse is widely used as an animal model with which to investigate
the endocrine regulation of spermatogenesis. Chronic treatment of these GnRH-deficient mice with
estradiol is known to induce testicular maturation and restore qualitatively normal spermatogenesis. The
aim of the current studies was to investigate whether these effects of estradiol are direct effects in the
testis, or indirect actions via paradoxical stimulation of FSH secretion from the pituitary gland.
Methods: Initially, Western blot and immunohistochemistry were used to analyse tissues from hpg mice
to identify potential sites of action of estradiol. In the main study, hpg mice were treated for 50 days with
either an estradiol implant or daily injections of recombinant human FSH, or a combination of both, to
determine whether estradiol would have an additive or synergistic effect with FSH on testis development,
as assessed by histological analysis and stereological quantification of Leydig, Sertoli and germ cell
proliferation.
Results: Western blot analysis revealed ERα immunoreactive bands of appropriate molecular weight in
extracts of testis and pituitary glands from hpg mice, and immunohistochemical studies confirmed ERα in
nuclei of anterior pituitary cells and Leydig and peritubular cells in hpg mice. Histological and
morphometric analyses revealed that estradiol treatment alone was as effective as FSH in promoting
Sertoli cell production and proliferation of the seminiferous epithelium, resulting in the production of
elongating spermatids. Combined estradiol and FSH treatment did not produce a greater effect than either
treatment alone, though an increased dose of FSH significantly increased seminiferous tubule volume and
testis weight and increase Sertoli cell numbers further within the same time frame. In contrast, estradiol
caused substantial increases in the wet weight of the seminal vesicles, whereas FSH was without effect on
this tissue, and did not augment the actions of estradiol.
Conclusion: As ERalpha receptor is abundantly expressed in the pituitary gland of hpg mice, and estradiol
did not exert effects on testis development over and above those of FSH, we conclude that the action of
estradiol on testis development in hpg mice is predominantly via the stimulation of pituitary FSH release.
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Background
Traditionally, the regulation of mammalian spermatogen-
esis has been viewed as being dependent upon the inter-
actions of gonadotrophins and androgens, however,
recent observations in experimental rodents and man
have indicated additional roles for estrogen in this process
[[1,2] for reviews]. Human studies have demonstrated the
presence of aromatase in the testis together with the
expression of two splice variants of ERβ in somatic and
germ cell compartments, though expression of ERα
appears to be restricted to the efferent ductules [3]. The
importance of estrogen in male reproduction is illustrated
by the infertility displayed by men with inactivating muta-
tions in the gene encoding aromatase or ERα [4]. Mice
have been widely used to investigate the function of estro-
gens in male reproduction, indeed the targeted deletion of
estrogen receptors [5] and aromatase [6] provided the first
evidence for a role for estrogen in sperm production. In
contrast to primates, ERα is expressed abundantly in the
Leydig cells of mice, though it seems likely that the infer-
tility in male ERα knockout mice results from inadequate
fluid resorption in the efferent ductules rather than a pri-
mary deficit in spematogenesis [7]. The function of ERα in
the interstitial cells of the rodent testis is not understood.
We and other research groups have exploited the hypogo-
nadal (hpg) mouse [8], which cannot produce mature
GnRH decapeptide due to a truncation in the GnRH gene,
as a model to study the role of estrogen in male reproduc-
tive function [9,10]. Hpg mice are infertile because they do
not produce gonadotropin and, in consequence, testis
development does not proceed beyond the neonatal stage
[11]. It is well established that treatment of hpg mice with
LH can stimulate steroidogenesis [12] and treatment with
FSH and androgens can induce qualitatively normal sper-
matogenesis [13,14]. However, we have also observed
that chronic estradiol treatment alone can induce sperma-
togenesis in hpg mice [9,15,16], though this is associated
with paradoxical increases in pituitary and serum FSH
concentrations. The importance of this estrogen-induced
increase in FSH secretion is not known: it has not been
established whether estradiol acting directly at the level of
the testis is sufficient to produce qualitative spermatogen-
esis in hpg  mice or whether the effects of estradiol in
inducing spermatogenesis are more indirect, occurring via
the rise in FSH production.
This aim of the study was to investigate the relative contri-
bution of direct (testis) and indirect (pituitary) actions of
estradiol in stimulating spermatogenesis. The initial
objective of the study was to use immunohistochemistry
and Western blotting to localise ERα in the pituitary gland
and testis of hpg mice, in order to identify putative sites of
estrogenic action in promoting spermatogenesis in this
mutant strain. The main objective was to measure the
qualitative and quantitative effects of estradiol on testis
development and spermatogenesis in hpg  mice in the
presence and absence of rhFSH. If combined estradiol and
rhFSH treatment proved to be more effective than either
of these treatments alone (i.e. there was a synergistic
effect), we would conclude that these hormones exert sep-
arate actions. If, however, combined estradiol and rhFSH
treatment were to be only as efficacious as would be
expected from a higher rhFSH dose (i.e. an additive effect)
then we would conclude that estradiol most likely acts via
stimulation of FSH secretion.
Methods
General
All animal procedures were approved by the University of
Nottingham Local Ethical Review Committee and carried
out in accordance with the Animals Scientific Procedures
Act (UK) 1986 (project licence PPL 40/2372). Laboratory
Animal Science Association (LASA) guidelines were fol-
lowed for administration of substances [17]. Adult hpg
male mice were identified by their micropenis, reduced
anogenital distance and small scrotal sac.
Western blot procedure
Pituitary glands and testes from hpg and age-matched lit-
termates mice (approximately 135 days old) were placed
in phosphate-buffered saline at pH7.4 (PBS) containing a
protease inhibitor. Tissues were sonicated on ice for 3 × 10
sec, centrifuged at 1300 RPM for 5 min and the superna-
tant extracted and stored at -20°C until used. Testis and
pituitary protein were incubated at 100°C for 5 mins in
the presence of 5% mercaptoethanol. Samples were then
immediately cooled on ice and loaded onto the gel. Pro-
tein samples were separated on a 10% SDS gel and trans-
ferred to a nitrocellulose membrane (Amersham).
Membranes were blocked with 5% milk (Marvel) in PBS
at 25°C for 1 hour before incubation overnight at 4°C
with a polyclonal antisera raised in rabbit recognising ERα
(1:50 dilution of MC-20, Santa Cruz, USA). After over-
night incubation membranes were washed in PBS, then
PBS/Tween 20, and subsequently incubated with 1:2000
anti-rabbit IgG peroxidase conjugate (Sigma, Poole, UK).
Visualization of the protein was achieved using the super-
signal system (Pierce, USA). The molecular weight of the
protein was estimated by comparing its mobility with
standard marker proteins of known molecular weights.
The relative amounts of the protein indicated by the inten-
sity of the bands was evaluated by analysing scans of the
film and performing densitometry using the NIH Image
computer package.
Immunohistochemistry
Testis and pituitary tissue was fixed by immersion in 4%
paraformaldehyde, then embedded in paraffin wax so that
5 um sections could be cut on a microtome. Mounted sec-Reproductive Biology and Endocrinology 2008, 6:4 http://www.rbej.com/content/6/1/4
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tions were then placed in xylene to remove the paraffin
wax, and placed in decreasing concentrations of ethanol
and then tap water to rehydrate the tissue. The pituitary
and testis sections were subject to antigen retrieval in 0.01
M citrate buffer pH6 by microwaving at full power (650
W) for 2 × 5 mins. For the studies on estrogen receptor dis-
tribution, sections were washed in phosphate buffered
saline (PBS) buffer and blocked for endogenous peroxi-
dase with 3% hydrogen peroxide. Following rinsing in
PBS, samples were blocked with normal goat serum (Vec-
tor Labs, Peterborough, UK) then incubated overnight at
4°C with the previously validated rabbit polyclonal ERα
antiserum (MC-20, Santa Cruz) at a dilution of 1:50. Sec-
tions were washed in PBS and incubated with a bioti-
nylated anti-rabbit IgG at 25°C for 1 hour followed by an
avidin biotin horseradish peroxidase complex (Elite ABC:
Vector Labs, Peterborough, UK). Immunoreactivity was
revealed by incubation with diaminobenzidine (DAB)
and the reaction stopped by immersing sections in tap
water. Sections were counterstained with eosin. After
dehydration through increasing concentration of ethanol,
sections were mounted using DePeX mounting medium
(Sigma, Poole, UK).
For the studies on where the expression of the steroidog-
enic enzymes 3β hydroxysteroid dehydrogenase (3βHSD)
was used to identify Leydig cells, a similar protocol was
followed but omitting the pre-treatment with 3% hydro-
gen peroxide. Sections were incubated overnight in a pol-
yclonal rabbit anti-3βHSD antiserum (dilution of 1:1000)
donated by Prof Ian Mason, University of Edinburgh, and
previously validated for use in rodents [18,19]. Sections
were washed in PBS and incubated with a biotinylated
anti-rabbit IgG at 25°C for 1 hour followed by a fluores-
cein-avidin complex (Vector Labs). After washes in PBS
then distilled water, sections were coverslipped using
Vectashield (Vector Labs), sealed with nail polish and
viewed under a Leica DMRB Fluorecence microscope.
Experimental protocol: effects of estradiol and rhFSH
Under general anesthesia, male hpg mice ranging in age
from 3–7 months were implanted with either a subcuta-
neous capsule containing 2% estradiol (n = 11) or choles-
terol (n = 15) as previously described [9]. Subgroups of
hpg  mice bearing estradiol implants were then treated
daily with 1 IU rhFSH (n = 6) or vehicle (n = 5) for 50
days. Correspondingly, subgroups of hpg  mice bearing
cholesterol implants were treated daily with 1 IU rhFSH
(n = 5) or 5 IU rhFSH (n = 6) or vehicle (n = 5) for 50 days.
The doses of rhFSH were based on those used in a previ-
ous dose-response study in hpg mice and were designed to
produce a submaximal (1 IU/day) and a maximal (5 IU/
day) effect [14]. On experimental day 50, blood samples
were collected by cardiac puncture under terminal
anesthesia (sodium pentobarbitone, i.p.) 2 h after the last
FSH treatment. Blood was allowed to clot at room temper-
ature before being spun at 13000 rpm and then serum
samples were stored at -20°C until assayed. After blood
collection, the pituitary, testes, epididymides and seminal
vesicles were excised, trimmed of fat and connective tissue
and weighed. One testis was placed in Bouin's fixative,
and subsequently embedded in paraffin wax so that 5 um
sections could be cut on a microtome and stained with
haematoxylin-eosin for light microscope analysis.
Morphometric (stereological) analyses
The primary morphometric aims were to estimate vol-
umes of seminiferous tubules and seminiferous epithe-
lium within testes. To this end, stereological estimates
[20,21] were made on tissue images randomised for loca-
tion and orientation by a multistage systematic uniform
random sampling design. Approximately four sections per
testis, and six microscopical fields per section, were ran-
domly chosen for analysis. Fields were sampled as images
captured on a Leica DM4000B brightfield microscope via
OpenLab software (Improvision, Coventry, UK) and
printed to a final magnification of ×1000 using a stage
micrometer scale as an external calibration standard. Vol-
ume densities of testicular ingredients were determined by
randomly superimposing a transparent grid comprising
35 test points arranged in a quadratic array. Test points
falling on a given testis and its ingredients were summed
over all fields from all sections. The total number of
points landing on a given ingredient (tubule, lumen, epi-
thelium), divided by the total number of points landing
on the testis sections, provided an unbiased estimate of its
volume density. The absolute volume of each ingredient
per testis was estimated subsequently from the product of
the volume density and the processed testicular volume.
In order to assess whether changes in tubule volume were
attributable to changes in calibre or total length, mean
diameters of seminiferous tubules were measured after
selecting tubules using an unbiased counting frame [20].
In the case of elliptical profiles, the short axis was meas-
ured. To give an indication of the degree of germ cell
development, each of the 24 fields per testis collected for
stereological analysis was also scored by an observer blind
to the experimental treatment to indicate the most mature
germ cell type present.
Quantitative assessment of Leydig and Sertoli cell num-
bers was made in order to obtain relative measures of net
cell proliferation. Estimates were obtained by randomly
superimposing a forbidden line unbiased counting frame
[20] on enlarged photomicrographs of tissues immunos-
tained for 3β-HSD (Leydig cell marker) or on tissue sec-
tions stained with haematoxylin and eosin where the
nuclei of Sertoli cells could be unequivocally identified by
their characteristic location and appearance (eg tripartite
nucleolus, [11]). Using this counting frame, the numbersReproductive Biology and Endocrinology 2008, 6:4 http://www.rbej.com/content/6/1/4
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of nuclear profiles per unit area of testis were used to
obtain model-based estimates of the numbers of nuclei
per unit volume of tissue (Nv). To this end, we obtained
estimates of section thickness (T, always 5 μm) and the
mean diameters (D, in μm) of nuclei for each cell type. To
estimate the mean nuclear diameter, the diameters of 10
randomly selected nuclei were measured. On the explicit
assumption that each cell contains a single nucleus, the
total number of specific cell types per testis (N) was then
calculated from
N = Nv × Vtestis
where Vtestis represents testis volume (cm3) was calculated
by dividing testis mass (g) by tissue density. The latter was
taken to be 1.05 g/cm3 [22].
Hormone assays
Serum FSH concentrations were measured using both a
commercially available human FSH ELISA kit (IDS Ltd
UK) to determine the levels of recombinant hFSH circulat-
ing, and a rat FSH immunoradiometric kit (IDS Ltd UK)
in order to estimate the total circulating FSH concentra-
tions (i.e. endogenous and exogenous). FSH concentra-
tions in extracts of mouse pituitary gland, or in untreated
wild-type mouse serum, did not dilute in parallel with the
rat standards, and there was substantial cross reactivity of
rhFSH in the rat IRMA (1 mIU rhFSH reading as approxi-
mately 1.5 ng/ml of the rat FSH standard) so all experi-
mental samples were compared at the same dilution in a
single assay and must be considered as relative concentra-
tions rather than absolute values. The minimum detection
limit in the rat FSH IRMA was 0.2 ng/ml and the intra-
assay CV was 2.0%. The minimum detection limit in the
human FSH ELISA was 1 mIU/ml and the intra-assay CV
was 7.5%.
Statistical analysis
Data for organ weights were analysed using one-factor
ANOVA followed by Tukey's multiple comparison test
(Prism v4.0, GraphPad Software, San Diego, CA). FSH val-
ues were analysed using Kruskal-Wallis non-parametric
tests (also Prism) because when values were below the
limit of detection of the assay they were assigned that
value for the purposes of statistical analysis.
Results
Estrogen receptor immunoreactivity in the pituitary gland 
and testis
Western blots revealed a clear band of ERα-immunoreac-
tivity in extracts of pituitary tissue from adult hpg mice at
a molecular weight of approximately 64 KDa (Fig. 1, top).
There was no significant difference in abundance compar-
ing samples from hpg (n = 4) and wild type (n = 4) mice.
ERα-immunoreactive bands were also observed at
approximately 64 KDa in extracts of testis from both hpg
and wild-type mice, plus a slightly lower molecular weight
band which is likely to be a degradation artefact (Fig. 1,
bottom). No statistical difference in abundance of the two
bands between the genotypes was observed (Fig. 1).
Immunohistochemistry revealed a clear nuclear localiza-
tion of ERα in anterior pituitary cells in both hpg mice and
wild-type litter mates (Fig. 2). ERα-immunoreactivity was
prominent in the nuclei of both Leydig cells and peritubu-
lar myoid cells in testes from hpg mice (Fig. 2, left). Leydif
cells in the age-matched wild-type testis also expressed
ERα-immunoreactivity (Fig. 2, right), and some peritubu-
lar cells also expressed ERα (Fig. 2, right). In addition, in
wild-type mice there ws some positive immunostaining of
cells adjacent to the basal membrane with an irregular
shaped nucleus which are almost certainly Sertoli cells
(Fig. 2, right). The immunoreactive signal was absent
when the primary antiserum was replaced with rabbit IgG
(Fig. 2, bottom left).
Effects of estradiol and rhFSH on reproductive organ 
weight
Treatment with estradiol alone or with 1 IU rhFSH alone
significantly (P < 0.05) increased testicular weight in hpg
mice, as compared to the vehicle-treated controls
(Fig. 3A). The combined estradiol plus 1 IU rhFSH treat-
ment did not increase testis weight above that of the indi-
vidual treatments (Fig. 3A). The high dose rhFSH
treatment (5 IU) did produce a further increase in testis
weight, such that testes weights were four-fold greater
than the controls (P < 0.001; Fig. 3, top). The low dose (1
IU) rhFSH treatment produced no significant increase in
Western blot analysis of ERα immunoreactivity Figure 1
Western blot analysis of ERα immunoreactivity. 
Examples of a Western blot analysis of extracts of pituitary 
gland (top) and testis (bottom) from hypogonadal (hpg) and 
age-matched wild-type (+/+) mice. Membranes were stained 
with MC-20 ERα antiserum (Santa Cruz).
hpg +/+
pituitary
+/+ hpg
64KDa
ER
testis
hpg +/+ hpg hpg +/+ +/+
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epididymal weight (Fig. 3B), whereas in both the groups
receiving estradiol (i.e. estradiol alone or estradiol with 1
IU rhFSH) there was a significant increase (P < 0.001,
Fig. 3B). Treatment with 5 IU rhFSH produced a smaller
increase in epididymal weight (Fig. 3B). Likewise, in both
the groups receiving estradiol there was a large increase in
the weight of the seminal vesicles (P < 0.001, Fig. 3C),
whereas neither of the FSH treatments affected this organ
(Fig. 3C).
Serum FSH concentrations
Assay of serum samples using the human FSH kit con-
firmed that rhFSH was detectable in mice treated with
rhFSH (Fig. 3D), and that the higher dose treatment (5
IU) produced a significantly higher circulating concentra-
tion of FSH (P < 0.01; Fig. 3D). There was significant
crossreactivity of rhFSH in the rat RIA FSH assay so we
were unable to measure endogenous mouse FSH directly
in the animals treated with rhFSH. However, some infer-
ences can be made. In the hpg mice receiving estradiol
only, there was a significant increase (p < 0.05) in circulat-
ing FSH (Fig. 3E). Total serum FSH was also significantly
higher (p < 0.05) in hpg mice receiving 1 IU rhFSH when
compared to the control hpg  group (Fig. 3E), and
increased proportionately in the mice receiving 5 IU (Fig.
3E). In the hpg mice receiving both estradiol and 1 IU
rhFSH there was also a proportionate increase in FSH
compare to the hpg mice receiving estradiol only.
Testicular histology
Testes from hpg mice that were treated with cholesterol
implants and vehicle had a characteristic undeveloped
appearance, with small-diameter seminiferous tubules
lacking a lumen (Fig. 4, Table 1) and Sertoli cells fre-
quently located close to the basal lamina (Fig. 4). Round
and elongating spermatids were not observed and germ
cell development in this control group did not develop
past the primary spermatocyte stage. Testicular sections
from all the other groups of hpg mice treated with estra-
diol or rhFSH revealed that the increase in testicular
weight was a reflection of development of the seminifer-
ous epithelium, and presence of lumina (Fig. 4, Table 1).
Elongating spermatids were present in the majority of
tubules, though these were more abundant in tubules in
the group treated with the higher dose of FSH (Fig. 4).
Morphometric analysis revealed that both estradiol alone
and 1 IU/day rhFSH alone increased the volume of the
seminiferous epithelium and thus the total tubule volume
compared to the cholesterol+vehicle treated control hpg
mice (Table 1). The combined estradiol + 1 IU/day rhFSH
also significantly increased these parameters compared to
the controls, but this combined treatment did not increase
significantly any parameter of tubule development com-
Immunohistochemical localization of ERα in hpg mice Figure 2
Immunohistochemical localization of ERα in hpg 
mice. Examples of immunohistochemical localization of ERα 
in the pituitary gland (upper panels) or testis of hypogonadal 
mice (hpg, left panels) or age-matched wild-type mice (+/+, 
right panels). Note that many anterior pituitary cells express 
nuclear ERα immunoreactivity in both hpg and +/+ mice. 
ERα-ir is abundant in the Leydig cells (lc) and peritubular 
myoid cells (pt) in the testis of hpg mice, and is also present 
in some Sertoli cells (sc) in wild-type mice. Bottom left panel 
shows a control study in which the primary antiserum was 
omitted, the section is from a hpg testis. All photomicro-
graphs were taken at the same magnification so the 20 μm 
scale bar in top left panel applies to all panels
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Organ weights and serum FSH concentrations in hpg mice  after treatment with estradiol and/or rhFSH Figure 3
Organ weights and serum FSH concentrations in hpg 
mice after treatment with estradiol and/or rhFSH. 
Wet weight of paired testes (top), epididymides (second 
panel) and seminal vesicles (middle panel), and serum con-
centrations of FSH of male hpg mice as determined in the 
human FSH ELISA (fourth panel) and the rat RIA (bottom). 
Groups of mice were treated for 50 days with subcutaneous 
implants containing either cholesterol (chol) or 2% estradiol 
(E), and also daily treatment with vehicle, 1 or 5 U of recom-
binant human FSH (Gonal-F™). Values are group mean ± 
SEM, group sizes as indicated. *P < 0.05, **P < 0.01 and ***P 
< 0.001 vs group treated with cholesterol implants and vehi-
cle; @P < 0.01 vs all other groups.
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Testis histology after treatment with estradiol and/or rhFSH Figure 4
Testis histology after treatment with estradiol and/or 
rhFSH. Representative examples of testicular histology for 
hpg mice receiving subcutaneous implants containing either 
cholesterol (chol) or 2% estradiol (E), and also daily treat-
ment with vehicle, 1 or 5 U of recombinant human FSH 
(Gonal-F™) for 50 days. Scale bars represent 50 μm.Reproductive Biology and Endocrinology 2008, 6:4 http://www.rbej.com/content/6/1/4
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pared to hpg mice receiving either of the treatments alone
(Table 1). Daily treatment with 5 IU rhFSH did produce
significantly greater increases in seminiferous epithelium
volume, tubule volume and total tubule length as com-
pared to the separate or combined estradiol and 1 IU/day
rhFSH treatments (Table 1). The 3β-HSD immunostain-
ing revealed that Leydig cells were abundant in the inter-
stitial compartments of the testes from hpg mice (Fig. 5),
but only the daily treatment with 5 IU rhFSH produced a
significant increase in Leydig cell numbers (Fig. 6, lower
panel). In contrast, treatment with estradiol alone signifi-
cantly increased the number of Sertoli cells (Fig. 6, upper
panel), as did treatment with the higher dose of rhFSH, as
did the combined treatment of estradiol plus 1 IU rhFSH/
day (Fig. 6).
Discussion
The first objective of these studies was to confirm the
expression of ERα receptors in the pituitary gland and tes-
tis of hpg mice. Complementary immunohistochemical
and Western blot studies revealed that ERα immunoreac-
tivity is present in both the pituitary and testis of hpg mice
at levels comparable to that in wild-type litter mates. The
immunohistochemical studies demonstrated that the dis-
tribution of ERα in the testis of the hpg  mouse was
restricted to putative Leydig cells in the interstitium and
peritubular myoid cells, consistent with previous studies
in the mouse [23]. Interestingly, we also observed ERα
immunoreactivity in angular nuclei adjacent to the basal
lamina in testes from wild-type littermates, these are very
likely to be Sertoli cells. Previous studies in mice have not
reported ERα expression in this cell type [23]. Our obser-
vations suggest that estradiol could potentially act via ERα
in both the pituitary and testis in the hpg mouse. We were
unable to confirm using immunohistochemistry whether
ERβ is also expressed in the testis of the hpg mice due to
technical limitations of the antiserum, but Western blots
did reveal protein bands of the appropriate molecular
weight of ERβ in tissues from both hpg and wild-type mice
(data not shown). Previous studies have provided rather
conflicting evidence for ERβ expression in the mouse tes-
tis, some studies demonstrating ERβ expression in the
Leydig cells and elongating spermatids of adult mice [24],
others reporting a developmental decline in ERβ expres-
sion in the mouse testis, with immunoreactivity being
undetectable in the adult [25]. As ERβ expression does not
appear to be required for normal testis function in the
mouse [26], our studies have focussed on the role of the
ERα receptor.
We again observed robust stimulatory effects of estradiol
treatment on the testis in hpg mice, consistent with our
previous studies [9,15,16]. The current study revealed that
these effects of estradiol were both qualitatively and quan-
titatively very similar to the effects of treatment with FSH.
It is well established that treatment with FSH alone will
induce testicular development in hpg mice [14], though
we observed a greater degree of development. In our
study, both doses of rhFSH induced germ cell develop-
ment up to the elongating spermatid stage and the also
the formation of small lumina in the tubules, whereas
Singh and Handelsman [14] reported that the same doses
of rhFSH applied for the same duration (50 days) mainly
stimulated premeiotic germ cell proliferation, and that
relatively few cells progressed to the round spermatid
stage. We observed a significant increase in numbers of
Sertoli cells after estradiol and high dose rhFSH treatment,
which Singh and Handelsman [14] did not detect. Given
that the estradiol treatment clearly elevated circulating
FSH concentrations, this observation is consistent with
the key role of FSH in Sertoli cell proliferation in mice
[27], and with more recent studies where genetic induc-
tion of FSH production in hpg mice has increased Sertoli
cell production [28]. We also observed an increased
number of Leydig cells in hpg mice treated with the high
dose of FSH. Stimulatory actions of FSH on Leydig cell
activity and morphology have been reported previously in
hpg mice and are likely to reflect indirect actions mediated
by paracrine output from Sertoli cells [29]. Unfortunately
insufficient serum was available to measure circulating
Table 1: Morphometric analyses of testes in hpg mice after treatment with estradiol and/or rhFSH
cholesterol vehicle estradiol vehicle cholesterol 1 IU FSH estradiol 1 IU FSH cholesterol 5 IU FSH
N 34455
body wt (g) 29.7 ± 3.2 30.0 ± 2.5 29.5 ± 2.5 29.8 ± 2.8 29.0 ± 3.2
testis wt (mg) 12.0 ± 0.1 24.2 ± 1.8a 27.2 ± 3.3a 27.2 ± 1.7a 46.6 ± 4.8abc
tubule diameter (μm) 50.3 ± 0.7 71.6 ± 3.3a 66.3 ± 1.6a 72.3 ± 2.2a 77.3 ± 3.5a
tubule volume (μl) 3.8 ± 0.7 11.2 ± 1.1a 12.1 ± 0.39 12.2 ± 1.1a 21.8 ± 2.3abc
tubule length (m) 2.2 ± 0.4 2.8 ± 0.2 3.3 ± 0.2 3.0 ± 0.2 4.6 ± 0.3abc
tubule (% testis) 76.9 ± 9.9 91.3 ± 1.4 92.5 ± 0.8a 87.9 ± 1.5 94.0 ± 0.7a
sem epith vol (μl) 3.6 ± 0.6 9.9 ± 0.9a 11.0 ± 0.2a 10.5 ± 0.9a 19.4 ± 2.0abc
lumen volume (μl) 0.1 ± 0.1 1.3 ± 0.3 1.6 ± 0.3 1.1 ± 0.1 2.4 ± 0.4
Values are group mean ± SEM, n = number of mice where complete stereological analysis was carried out. aP < 0.05 vs cholesterol + vehicle, bP < 
0.05 vs estradiol + vehicle, cP < 0.05 vs cholesterol + 1 IU FSH. sem epith vol = seminiferous epithelium volumeReproductive Biology and Endocrinology 2008, 6:4 http://www.rbej.com/content/6/1/4
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testosterone concentrations after the various experimental
treatments as we considered it to be much more impor-
tant to measure endogenous and recombinant FSH in the
serum that we collected in order to verify the efficacy of
our treatment protocols. In our previous studies we have
been unable to measure detectable increases in either
serum testosterone [9,15] or in intratesticular testosterone
[15] after estradiol treatment, but on the basis of previous
studies in hpg mice it seems likely that the FSH treatments
would have increased testicular androgen production
[29].
Numbers of Leydig and Sertoli cells in hpg mice after treat- ment with estradiol and/or rhFSH Figure 6
Numbers of Leydig and Sertoli cells in hpg mice after 
treatment with estradiol and/or rhFSH. Estimates of 
numbers of Leydig cells (top) and Sertoli cells (bottom) in 
testes of hpg mice that had been treated for 50 days with 
subcutaneous implants containing either cholesterol (chol) or 
2% estradiol (E), and also daily treatment with vehicle, 1 or 5 
U of recombinant human FSH (Gonal-F™). Values are group 
mean ± SEM, group sizes as indicated. *P < 0.05 and ***P < 
0.001 vs group treated with cholesterol implants and vehicle.
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Leydig cells in hpg mice after treatment with estradiol and/or  rhFSH Figure 5
Leydig cells in hpg mice after treatment with estra-
diol and/or rhFSH. Representative examples of 3β-HSD 
immunostaining in hpg mice receiving subcutaneous implants 
containing either cholesterol (chol) or 2% estradiol (E), and 
also daily treatment with vehicle, 1 or 5 U of recombinant 
human FSH (Gonal-F™) for 50 days. Scale bars represent 50 
μm.
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Though model-based, our estimates of cell numbers are
consistent with those obtained by ourselves and others
using more robust, design-based stereological procedures
[9,27,30,31]. An important difference between the current
study and that of Singh and Handelsman [14] is that in
the latter study the 50-day rhFSH treatment was initiated
at a juvenile age (day 21), whereas we treated hpg mice at
an "adult" age. We have previously observed that there is
a degree of spontaneous testicular development in hpg
mice probably reflecting a low level of GnRH-independ-
ent production of gonadotropins [1]. Thus, our experi-
mental rhFSH treatments may well have been
superimposed upon a marginally higher endogenous
level of testicular development or androgen production,
and given the key role for androgens in murine sperma-
togenesis [13,15] this seems a highly likely explanation
for the differences between the current and the previous
study.
The key outcome of the current studies is that the com-
bined estradiol and rhFSH did not  produce a greater
degree of stimulation of the seminiferous epithelium that
treatment with either hormone alone. This is contrary to
our initial prediction, and to studies in the neonatal rat
where combined treatment with estradiol benzoate and
purified human FSH produce effects on development of
the seminiferous epithelium not seen after treatment with
either hormone alone, including increased tubule diame-
ters, induction of a lumen and increased numbers of pach-
ytene spermatocytes [32]. The observation that treatment
with a higher dose of rhFSH (5 IU daily) did increase the
volume of the seminiferous epithelium and tubules fur-
ther demonstrates that the lack of additive or synergistic
effect is not a consequence of maximal proliferation rates
already being achieved. Given the qualitative and quanti-
tative similarity of the effects of estradiol and rhFSH that
we observed, we conclude that the primary action of estra-
diol on testis function is indirect, via the stimulation of
FSH release, in the hpg  mouse experimental model.
Although this stimulatory effect of estradiol may seem like
a paradoxical response in a male mammal, it was demon-
strably the case that circulating FSH levels were increased
in this and previous studies in the hpg mouse. This para-
doxical effect in the male is not due to incomplete mascu-
linization of the hpg mouse [16], rather it appears to be a
reflection of the fact that development of the reproductive
axis in the hpg mouse is arrested at a neonatal stage [1,11]
when steroid negative feedback pathways have not yet
developed. It is worth noting that certain actions of estra-
diol on the male reproductive tract in mice are highly
likely to be direct actions. In the current study we
observed that estradiol treatment produced a substantial
increase in the wet weight of the seminal vesicles, whereas
FSH had no effect on this tissue nor did it augment the
actions of estradiol. This is consistent with a previous
study in the hpg mouse [9], which also provided evidence
for direct effects of estradiol on the prostate gland [9].
Recent evidence points to an autocrine or paracrine role
for estradiol in the testis during fetal and early neonatal
development whereby it inhibits production of androgens
by Leydig cells [33]. Perhaps the endocrine actions of
estradiol revealed in the hpg mouse represent a physiolog-
ical role in co-ordinating early development. Whilst estra-
diol production acts within the testis to retard early
androgen production, it also acts in the pituitary gland to
stimulate FSH production and thereby promote early Ser-
toli cell proliferation. Thus, when pubertal increases in LH
production eventually occur and thereby stimulate andro-
gen production, the somatic cell complement within the
tubules has already been established and will support the
androgen-driven spermatogenesis.
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